Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX-HAIC + Lenvatinib + Envolizumab in Potentially Resectable HCC
NCT06143579Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2023
- Primary completion
- Mar 2025
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
01
Overview
A Phase 2 trial of envafolimab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
envafolimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06143579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06143579.